UBS raised the firm’s price target on Neurocrine (NBIX) to $176 from $162 and keeps a Buy rating on the shares. The firm expects Neurocrine to ...

FY25 revenue consensus $69.48B. Anticipates another year of services growth. Does not anticipate a significant change in dealer inventory of ...

But notably, you still need to tend to your Sim. You even need to make sure that they use the bathroom now and again, or else ...

Deckers Outdoor Corporation (NYSE:DECK) reported strong financial results for the third quarter of fiscal year 2025, ...

They’re de facto endorsing government interference with the church—the very government interference with the church that they ...

Data from Extu sales incentive programs shows that companies who implement their programs see an average 30% increase in sales. Achieving this growth is largely dependent on the program's ...

Presented by Lucchese Bootmaker, the exhibition takes visitors on a journey through the history of one of the most iconic symbols of the American West: the cowboy boot.

Ike Boruchow; Analyst; Wells Fargo Securities, LLC ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales rose ...

Nathan Baxter; Chief Operating Officer, Executive Vice President; Scotts Miracle-Gro Co Jon Andersen; Analyst; William Blair & Co., LLC Eric Bossard; Analyst; Cleveland Research Company ...